Linked from

The 26 pages that link to Myasthenia gravis, each with the reason it gives.

• AcetylcholineRelated: The disease weakens muscles by reducing their response to acetylcholine.

• Neuromuscular junctionRelated: Reduced receptor function weakens the muscle response to nerve signals.

• ElectromyographyRelated: Specialized EMG methods can detect impaired neuromuscular transmission.

• DysphagiaRelated: Fatigable weakness can involve muscles used for chewing and swallowing.

• Guillain–Barré syndromeCompared with: Both can cause weakness, but myasthenia gravis targets the neuromuscular junction and often fluctuates with use.

• Botulinum toxinCompared with: Both impair muscle activation, but this disease usually targets postsynaptic receptors rather than presynaptic release.

• Synaptic transmissionRelated: It shows how postsynaptic disruption can weaken transmission to muscle.

• Muscle weaknessBroader topic: Its weakness often worsens with repeated activity and improves with rest.

• Excitation-contraction couplingCompared with: It disrupts excitation before the muscle’s intracellular coupling sequence begins.

• ThymusRelated: Thymic abnormalities, including thymoma, are associated with this autoimmune disease.

• BotulismCompared with: It can cause fatigable weakness, but usually lacks botulism’s descending acute paralysis pattern.

• Cholinergic crisisCompared with: Its weakness may be mistaken for cholinergic crisis, especially when acetylcholinesterase inhibitors are used.

• Muscular dystrophyCompared with: Its weakness arises from impaired neuromuscular transmission rather than inherited muscle-protein defects.

• AutoantibodyBroader topic: Autoantibodies against neuromuscular-junction proteins can weaken muscle signaling.

• Acetylcholinesterase inhibitorRelated: Acetylcholinesterase inhibitors can improve muscle strength by prolonging acetylcholine action.

• AzathioprineRelated: Its slower immunosuppressive effect can help control disease and reduce glucocorticoid requirements.

• Plasma exchangeRelated: Exchange can temporarily lower pathogenic antibodies during severe worsening or before selected procedures.

• Bernard KatzRelated: Katz’s synaptic framework helps distinguish reduced transmitter release from impaired postsynaptic response.

• PlasmapheresisRelated: Plasma exchange can rapidly reduce disease-causing antibodies during severe exacerbations.

• Synaptic cleftRelated: Antibodies commonly reduce postsynaptic acetylcholine receptors across the cleft.

• MyopathyCompared with: Its fluctuating weakness can resemble myopathy, but the defect lies at the nerve-muscle synapse.

• NeostigmineRelated: Neostigmine can improve muscle strength by increasing acetylcholine at the neuromuscular junction.

• Bell's palsyCompared with: Fluctuating weakness, often affecting the eyes, differs from the sudden one-sided pattern.

• Myotonic dystrophyCompared with: Weakness may resemble myotonic dystrophy, but delayed relaxation and repeat expansions point elsewhere.

• Glycogen storage disease type IICompared with: It can cause weakness, but unlike Pompe disease it is not a glycogen-storage disorder.

• HyporeflexiaCompared with: Strength may be weak while tendon reflexes are usually preserved, unlike many neuropathies.